Safety and immunogenicity of a ChAdOx1 vaccine against Rift Valley fever in UK adults: an open-label, non-randomised, first-in-human phase 1 clinical trial
Journal article
Jenkin D. et al, (2023), The Lancet Infectious Diseases, 23, 956 - 964
Evaluation of T cell responses to naturally processed variant SARS-CoV-2 spike antigens in individuals following infection or vaccination
Journal article
Yin Z. et al, (2023), Cell Reports, 42, 112470 - 112470
Higher antigen occupancy of high avidity CSP serum antibodies associates with protection against human malaria
Journal article
Li K. et al, (2023), Biophysical journal, 122, 144a - 145a
A tool for evaluating heterogeneity in avidity of polyclonal antibodies.
Journal article
Li K. et al, (2023), Frontiers in immunology, 14
Efficacy and immunogenicity of R21/Matrix-M vaccine against clinical malaria after 2 years' follow-up in children in Burkina Faso: a phase 1/2b randomised controlled trial.
Journal article
Datoo MS. et al, (2022), The Lancet. Infectious diseases, 22, 1728 - 1736
Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: An open-label partially-randomised ascending dose phase I trial
Journal article
Madhavan M. et al, (2022), eBioMedicine, 85, 104298 - 104298
Safety and immunogenicity of a simian-adenovirus-vectored rabies vaccine: an open-label, non-randomised, dose-escalation, first-in-human, single-centre, phase 1 clinical trial
Journal article
Jenkin D. et al, (2022), The Lancet Microbe, 3, e663 - e671
Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV
Journal article
Ogbe A. et al, (2022), JCI Insight, 7
CMV-associated T cell and NK cell terminal differentiation does not affect immunogenicity of ChAdOx1 vaccination
Journal article
Sharpe HR. et al, (2022), JCI Insight, 7
Safety and immunogenicity of ChAdOx1 MERS vaccine candidate in healthy Middle Eastern adults (MERS002): an open-label, non-randomised, dose-escalation, phase 1b trial
Journal article
Bosaeed M. et al, (2022), The Lancet Microbe, 3, e11 - e20
A single dose of ChAdOx1 Chik vaccine induces neutralizing antibodies against four chikungunya virus lineages in a phase 1 clinical trial
Journal article
Folegatti PM. et al, (2021), Nature Communications, 12
AZD1222/ChAdOx1 nCoV-19 vaccination induces a polyfunctional spike protein–specific TH1 response with a diverse TCR repertoire
Journal article
Swanson PA. et al, (2021), Science Translational Medicine, 13
Safety and immunogenicity of ChAdOx1 MERS vaccine candidate in healthy Middle Eastern adults (MERS002): an open-label, non-randomised, dose-escalation, phase 1b trial.
Journal article
Bosaeed M. et al, (2021), The Lancet. Microbe
Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection
Journal article
Feng S. et al, (2021), Nature Medicine, 27, 2032 - 2040
Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)
Journal article
Flaxman A. et al, (2021), The Lancet, 398, 981 - 990
Efficacy and Safety of a Modified Vaccinia Ankara-NP+M1 Vaccine Combined with QIV in People Aged 65 and Older: A Randomised Controlled Clinical Trial (INVICTUS)
Journal article
Butler C. et al, (2021), Vaccines, 9, 851 - 851
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial
Journal article
Frater J. et al, (2021), The Lancet HIV, 8, e474 - e485
Author Correction: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses
Journal article
Barrett JR. et al, (2021), Nature Medicine, 27, 1113 - 1113
Author Correction: T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial
Journal article
Ewer KJ. et al, (2021), Nature Medicine, 27, 1116 - 1116
Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial
Journal article
Datoo MS. et al, (2021), The Lancet, 397, 1809 - 1818